The quality-adjusted life year (QALY) metric took center stage during a recent panel at the International Society for Pharmacoeconomics and Outcomes (ISPOR) 2019 meeting in New Orleans, Louisiana.
Panelists during the discussion, “The Controversial QALY: Is There a Middle Ground in the Debate?”, highlighted individual perspectives on the pros and cons of the metric.
The panel included:
- Jennifer Bright, Innovation and Value Initiative executive director;
- Lou Garrison, University of Washington Pharmaceutical Outcomes Research and Policy program assistant director;
- Eleanor Perfetto, National Health Council executive vice president; and
- Andrew Lloyd, health economics consultant.